Palisade Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PALI research report →
Range $2 – $7
Price Chart
About the company
Palisade Bio, Inc. , a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease.
- CEO
- J. D. Finley
- IPO
- 2007
- Employees
- 14
- HQ
- Denver, CA, US
Get TickerSpark's AI analysis on PALI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $150.58M
- P/E
- -3.79
- PEG
- -0.01
- P/S
- 301.15
- P/B
- 1.58
- EV/EBITDA
- -0.82
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -9625.40%
- Net Margin
- -8739.20%
- ROE
- -35.60%
- ROIC
- -42.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,056,000
- Net Income
- $-16,781,000-16.2%
- EPS
- $-0.30+97.1%
- OCF Growth
- +11.0%
- FCF Growth
- +11.0%
- 52W High
- $2.86
- 52W Low
- $0.84
- 50D MA
- $1.37
- 200D MA
- $1.81
- Beta
- 1.62
- RSI (14)
- 25
- Avg Volume
- 3.19M
No earnings-call transcripts are available for PALI yet.
- Free Float
- 92.2%
- Shares Outstanding
- 179.28M
- Float Shares
- 165.34M
of shares held by institutions
126 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Soleus Capital Management, L.P. | 15.00M | ▲ 1.93M |
| Ameriprise Financial Inc | 14.57M | ▲ 3.49M |
| B Group, Inc. | 11.41M | 0 |
| Blackrock, Inc. | 11.10M | ▲ 659.13K |
| Janus Henderson Group Ltd. | 10.69M | ▲ 10.69M |
| Jupiter Topco LLC | 10.69M | ▲ 10.69M |
| Octagon Capital Advisors LP | 10.28M | 0 |
| Perceptive Advisors LLC | 8.43M | 0 |
| Vanguard Capital Management LLC | 7.89M | ▲ 6.17M |
| Ra Capital Management, L.P. | 7.12M | 0 |
| Franklin Templeton Inc | 6.07M | ▲ 284.56K |
| Point72 Asset Management, L.P. | 5.87M | ▲ 619.86K |
Held by 115 ETFs
Biggest fund positions in PALI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Baltera Robert Jr. | buy | 50,000 |
| Oct 19, 26 | Capers Julien E. | other | 787,300 |
| Oct 19, 26 | Capers Julien E. | other | 0 |
| Oct 6, 26 | Jones Mitchell Lawrence | other | 2,555,266 |
| Oct 6, 26 | Jones Mitchell Lawrence | other | 2,620,850 |
| Oct 6, 26 | Jones Mitchell Lawrence | other | 1,031,102 |
| Oct 6, 26 | Jones Mitchell Lawrence | other | 65,584 |
| Oct 6, 26 | Finley John David | other | 3,059,800 |
| Oct 6, 26 | Finley John David | other | 3,227,384 |
| Oct 6, 26 | Finley John David | other | 1,411,982 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PALI coverage
Recent articles, reports, and earnings notes.
No research on PALI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PALI report →Palisade Bio Analysts Slash Their Forecasts After Q3 Results
benzinga.com · Nov 11
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
globenewswire.com · Nov 10
Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor
seekingalpha.com · Nov 2
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
globenewswire.com · Oct 28
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
globenewswire.com · Oct 20
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
globenewswire.com · Oct 12
Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
defenseworld.net · Oct 3
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
globenewswire.com · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.